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Figure 3. Standardized mean differences of active treatments for pain at
12 weeks comparing results from deferential placebo effect network and
single placebo effect network
Abstracts / Osteoarthritis and Cartilage 22 (2014) S7–S56 S25Results: We identiﬁed 140 studies including 37,908 participants with
an age range of 45 - 75 years. The proportion of women ranged
from 28% - 100%. For pain, IA placebo (SMD, 95% Credible Interval)
[0.28 (0.08, 0.48)] and topical placebo [0.20 (0.02, 0.38)] had sig-
niﬁcantly greater effects than oral placebo. The relative efﬁcacies and
the hierarchy of the active treatments were substantially changed by
ignoring the differential response to the placebo types (Figures 2 &
3). For example, in the differential placebo network model, IA and
topical therapies rank higher than oral, while in the non-differential
placebo network model, oral NSAIDs ranked higher.
Conclusions: Our results show that some types of placebo inter-
ventions are associated with greater responses. This supports the
notion that some placebo treatments can exert clinically relevant
effects. In other words, the method of treatment delivery might
have an important inﬂuence on outcome. These important differ-
ences also need to be accounted for in the design of future OA
studies.
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Purpose: The ﬁxed dose combination of glucosamine hydrochloride
and chondroitin sulfate (2 capsules GHclþCS; 250 mg and 200 mg,
respectively, three times daily) was found to be efﬁcacious compared to
placebo in subjects with knee osteoarthritis (OA) with severe pain in the
NIH-funded Glucosamine Arthritis Intervention Trial (GAIT) (N Engl J
Med 2006 Feb 23;354(8):795-808). The proportion of OA patients who
achieved the primary endpoint of a 20% improvement in pain was
similar between those randomized to GHclþCS and celecoxib 200 mg
daily in this 6-month symptom study. Subsequently, a phase IV
randomized controlled non-inferiority trial was designed to compare
the efﬁcacy of GHclþCS and celecoxib in patients with knee OA to
extend the ﬁndings from GAIT.
Methods: The Multicentric Osteoarthritis interVEntion Study with
Sysadoa (MOVES) was designed as a non-inferiority trial to compare the
efﬁcacy and safety of a ﬁxed dose combination of GHclþCS (Droglican,
Bioiberica SA, Barcelona, Spain) and celecoxib in patients with symp-
tomatic knee OA with severe pain. Patients were randomized in a
double-blind, double-dummy fashion to receive either 2 capsules of
Droglican (GHcl 250 mg and CS 200 mg) three times daily, or Celecoxib
200 mg capsule plus 5 placebo Droglican capsules per day. Patients
were eligible if they were aged 40 and above, fulﬁlled American College
of Rheumatology criteria for knee OA, had Kellgren-Lawrence (KL) grade2 or 3 radiographic severity and had a WOMAC pain scale of >301 units
(0-500 scale). Patients with high gastrointestinal or cardiovascular risk
were excluded. The primary outcome was the mean decrease in
WOMAC Pain subscale after 6 months of treatment; the non-inferiority
marginwas set at 40 (corresponding to 8 mm on a 0-100 mm scale) and
the sample size was calculated at 240 per group with 90% power. Mixed
model repeated measures was used to analyse the primary outcome;
time, treatment and time x treatment were included as ﬁxed effects.
Results: A total of 763 patients were screened and 606 randomized to
receive either Droglican (N¼304) or celecoxib (N¼302). Of these, 522
(86.1%) completed the 6-month trial and were included in the per-
protocol non-inferiority analysis; there was no difference in proportion
completing between groups. Mean (SD) age was 62.7 (8.9) years, 438
(83.9%) were women; KL grade 2 changes were present in 327 (62.6%).
The mean (SD) WOMAC pain score at randomization was 372.0 (41.8)
and 370.6 (41.4) in the Droglican and celecoxib groups, respectively.
The mean (SD) WOMAC pain score at 180 days was 185.8 (7.4) and
184.7 (7.6) in the Droglican and celecoxib groups, respectively, corre-
sponding to a mean (SEM) difference of 1.11 (10.63) units (95% con-
ﬁdence interval -21.99, 19.76) (P ¼ 0.917) that respects the non-
inferiority margin. These results were robust in sensitivity analyses
using the intention-to-treat population and when baseline observation
carried forward was used for imputation in both the per-protocol and
intent-to-treat populations. In addition, there was no signiﬁcant dif-
ference between the Droglican and celecoxib groups in the absolute
improvement in the WOMAC stiffness and function scales and the ﬁve
individual items of the WOMAC pain scale at 6 months. There was no
signiﬁcant difference in the proportion of patients with treatment-
emergent adverse events between the groups (50.7% overall); no
deaths occurred in this 6-month study.
Conclusions: These results demonstrated comparable efﬁcacy of a ﬁxed
dose combination of glucosamine hydrochloride and chondroitin sul-
phate (Droglican) to celecoxib for relief of severe knee pain in patients
with knee OA and a similar safety proﬁle. Further ongoing analyses will
examine key secondary endpoints including responder indices in this
population.
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Purpose: The aim of the present fMRI study was to objectively identify
the effects of Chondroitin Sulfate (CS) treatment on the brain response
to pressure painful stimulation in patients with radiological and clinical
knee osteoarthritis.
Material and methods: The current study was developed in the
Rheumatology Department and the MRI Research Unit of the Hos-
pital del Mar in Barcelona, from December 2010 to January 2013. This
is a phase IV, randomized, double-blind clinical trial in which
patients received CS (Condrosan, Bioiberica S.A.) 800 mg/day or
placebo for a 4-month treatment course. 64 patients were random-
ized (32 to placebo and 32 to CS), and ﬁnally 51 patients were
evaluable by ITT (27 in the placebo group and 24 in the CS group).
Patients were assessed at baseline and post-treatment. Two tests
were conducted in each session by applying painful pressure on the
patella surface and on the knee medial interline, using a MRI-com-
patible algometer, during the acquisition of two 6-min fMRI
sequences. Stimulus intensity to be applied in both fMRI sessions was
individually adjusted prior to baseline fMRI. Each subject was asked
to rate the subjective pain perceived during the whole fMRI sequence
immediately after fMRI acquisition using NRS. All fMRI data were
processed using the Statistical Parametric Mapping (SPM8) package,
Wellcome Department of Imaging Neuroscience, running in Matlab
